3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
17
Solid Tumor
3
Thrombocytosis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Brain Neoplasms
1
Blast Crisis
1
Anemia
1
Interventions
pembrolizumab
24
Paclitaxel
20
Carboplatin
19
Taxes
7
temsirolimus
6
Trastuzumab
6
Topotecan
5
Radiotherapy
5
Cisplatin
5
atezolizumab
4
Specimen Handling
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Gemcitabine
4
Docetaxel
4
Biopsy
4
Bevacizumab
4
olaparib
3
lenvatinib
3
dostarlimab
3
Sirolimus
3
Pemetrexed
3
Irinotecan
3
Interleukin-12 Subunit p35
3
Fulvestrant
3
Cetuximab
3
Albumin-Bound Paclitaxel
3
spartalizumab
2
gedatolisib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Endometrial Neoplasms
×
pertuzumab
×
Clear all
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled